D4476
(Synonyms: 4-[4-(2,3-二氢-1,4-苯并二氧杂环己-6-基)-5-(2-吡啶基)-1H-咪唑-2-基]苯甲酰胺,Casein Kinase I Inhibitor;D 4476;D-4476) 目录号 : GC13202
Inhibitor of CK1 and ALK5
Cas No.:301836-43-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1,2]: | |
|
Cell lines |
H4IIE, Hela and HCT116 cell lines |
|
Preparation method |
The solubility of this compound in DMSO is >19.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
H4IIE: 0-150 μM for 1 h; Hela: 50 μM; HCT116: 5-40 μM for 48 h |
|
Applications |
In H4IIE hepatoma cells, D4476 specifically inhibited the phosphorylation of endogenous forkhead box transcription factor O1a (FOXO1a) on Ser322 and Ser325 within its MPD, without affecting the phosphorylation of other sites. It was also found that although the treatment of in HCT116 cells with D4476 led to a partial p53-dependent growth arrest, the induction of p53-independent apoptosis by D4476 suggested a critical role for the MDM2-CK1 complex in maintaining E2F-1 anti-apoptotic signaling. |
|
References: [1] Rena G, et al. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004 Jan;5(1):60-5. [2] Huart AS, MacLaine NJ, Meek DW, Hupp TR.CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem. 2009 Nov 20;284(47):32384-94. |
|
D4476 is a relatively specific and cell-permeant inhibitor of CK1 and ALK5 with respective IC50 values of 0.3 and 0.5 μM at 0.1 mM ATP in vitro.[1]
CK1 (casein kinase 1) phosphorylates serine residues that are located close to another phosphoserine in multisite phosphorylation domains (MPDs). D4476 may be an ATP-competitive inhibitor of CK1. It weakly inhibits SAPK2a/p38 and does not inhibit PKB or SGK. In H4IIE cells, the site-specific phosphorylation (Ser322 and Ser325) of FOXO1a was inhibited at 50 and 125 μM, which reduced the initial rate of nuclear exclusion[1]. In Hela cells, the phosphorylation(Ser185) of RhoB caused by CK1 was inhibited by D4476 at 50 μM then the RhoB-dependent actin fiber formation was subsequently activated[2]. D4476 treatment has been observed to result in a partial p53-dependent growth arrest in HCT116 cells.[3]
References:
1. G. Rena, J. Bain, M. Elliott and P. Cohen, EMBO Rep 2004, 5, 60-65.
2. V. Tillement, I. Lajoie-Mazenc, A. Casanova, C. Froment, M. Penary, D. Tovar, R. Marquez, B. Monsarrat, G. Favre and A. Pradines, Exp Cell Res 2008, 314, 2811-2821.
3. A. S. Huart, N. J. MacLaine, D. W. Meek and T. R. Hupp, J Biol Chem 2009, 284, 32384-32394.
| Cas No. | 301836-43-1 | SDF | |
| 别名 | 4-[4-(2,3-二氢-1,4-苯并二氧杂环己-6-基)-5-(2-吡啶基)-1H-咪唑-2-基]苯甲酰胺,Casein Kinase I Inhibitor;D 4476;D-4476 | ||
| 化学名 | 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide | ||
| Canonical SMILES | C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 | ||
| 分子式 | C23H18N4O3 | 分子量 | 398.41 |
| 溶解度 | ≥ 19.9 mg/mL in DMSO, ≥ 41.5 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.51 mL | 12.5499 mL | 25.0998 mL |
| 5 mM | 0.502 mL | 2.51 mL | 5.02 mL |
| 10 mM | 0.251 mL | 1.255 mL | 2.51 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。